ReviewVaccines2025
Vaccine Development for Human Pneumoviruses.
Review in Vaccines, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
11 citing papers in PubMed.
- Genomic Surveillance of Human Metapneumovirus in the United States, 2010-2025.The Journal of infectious diseases · 2026Article
- A comprehensive look at Respiratory Syncytial Virus (RSV): from pathogenesis to prevention.Tropical diseases, travel medicine and vaccines · 2026Review
- Epidemiological Burden and Hospitalization Trends of Human Metapneumovirus in Spain (2016-2023): A Retrospective Study.Infectious diseases and therapy · 2026Article
- Genomic surveillance of human metapneumovirus in the United States, 2010 - 2025.medRxiv : the preprint server for health sciences · 2026Article
- Resurgence of human metapneumovirus: an overview of past and current trends.Archives of microbiology · 2026Review
- RSV vaccine development: advances and fusion protein-focused strategies.Frontiers in immunology · 2026Review
- Epidemiology, Distinct Seasonal Dynamics, and Age-Specific Characteristics of Eight Respiratory Viruses in Thailand, 2025.Journal of tropical medicine · 2026Article
- Human Metapneumovirus Circulation and Seasonality on a Global Scale, 2016-2025: Changes in Patterns and Epidemic Timing in the Pre- Versus Post-COVID-19 Era.Influenza and other respiratory viruses · 2025Article
- Epidemiology and Burden of Human Metapneumovirus Among Italian Adults in Outpatient and Inpatient Settings, 2014-2025.Influenza and other respiratory viruses · 2025Article
- Article
- Human metapneumovirus: an emerging public health threat and harbinger of a new pandemic.GMS hygiene and infection control · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
backgroundPneumoviruses are etiologic agents of respiratory tract infections and a major cause of morbidity and mortality worldwide, particularly affecting young children, the elderly, and individuals with underlying clinical conditions. These viruses are associated with a significant burden, particularly in low- and middle-income countries, where reported deaths attributable to respiratory syncytial virus (RSV) and human metapneumovirus (HMPV) in young children are important. Recent developments have been noted in the prevention of pneumoviral infections.
methodIn this review, we analyzed clinical trials of the approved RSV vaccines, as well as the recent prominent platform technologies used in RSV vaccine research. In addition, we discussed combination vaccines targeting RSV, HMPV, and Human Parainfluenza Virus Type 3 (HPIV3) that have entered clinical trials.
resultsRecent advancements include the approval of three RSV vaccine candidates: AREXVY
conclusionsWhile significant progress has been made in RSV vaccine development, especially with three approved candidates, the development of vaccines for HMPV remains an unmet medical need. Ongoing research in combination vaccines holds promise for broader protection against multiple respiratory viruses in the future.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.